Table 3.
Subgroup analysis and sensitivity analyses on primary outcomes.
| Subgroup | No. of studies | No. of patients | RR | 95%CI | I2 | P-value |
|---|---|---|---|---|---|---|
| Type of studies | ||||||
| RCT | 2 | 352 | 0.99 | 0.93–1.06 | 0% | 0.77 |
| Not-RCT | 4 | 251 | 1.25 | 1.04–1.51 | 51% | 0.02 |
| Outcome measurement | ||||||
| OS | 3 | 238 | 1.37 | 1.19–1.57 | 0% | <0.001 |
| DFS or PFS | 3 | 365 | 0.99 | 0.93–1.06 | 0% | 0.77 |
| Patients subgroup | ||||||
| Yes | 3 | 229 | 1.03 | 0.91–1.17 | 0% | 0.63 |
| No | 3 | 374 | 1.25 | 0.88–1.77 | 92% | 0.22 |
| HIPEC drugs | ||||||
| Oxaliplatin alone | 4 | 440 | 1.03 | 0.92–1.15 | 40% | 0.65 |
| Not oxaliplatin alone | 2 | 163 | 1.33 | 1.07–1.65 | 44% | 0.009 |
RCT, randomized controlled trials; OS, overall survival; DFS, disease-free survival; HIPEC, hyperthermic intraperitoneal chemotherapy; RR, risk ratio; CI, confidence interval.